Bioage Labs Inc (BIOA)

$BIOA BioAge Labs announces it will present new preclinical data on APJ agonism BioAge Labs announced that it will present new preclinical data supporting apelin receptor, APJ, agonism for the treatment of diabetic obesity and heart failure with preserved ejection fraction. The data will be presented at the American Diabetes Association's 85th Scientific Sessions, held June 20-23, 2025, in Chicago, Illinois. In their two presentations, the company will present data that demonstrated that in preclinical models of diabetic obesity and HFpEF, APJ agonist treatment had potential as monotherapy that could be enhanced in combination with incretin therapies. Enhanced glycemic control in diabetic obesity - Dr. Rubin's oral presentation will show that in mouse models of diabetic obesity, APJ agonist monotherapy reduced HbA1c to levels comparable to lean controls and improved glucose tolerance by 25%. Cardioprotective effects in HFpEF - Dr. Yan's poster will show that in a mouse model of obesity-associated heart failure, APJ agonist monotherapy reduced cardiac hypertrophy and suppressed markers of cardiac injury. Combination of APJ agonism with an incretin provided enhanced cardioprotective benefits and greater weight loss compared to either treatment alone.

$BIOA lots of pre clinical headlines this weekend. BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions BioAge Labs announced new preclinical data showing that its apelin receptor (APJ) agonist improved glycemic control and delivered cardioprotective effects in models of diabetic obesity and heart failure with preserved ejection fraction (HFpEF). The therapy also showed additive benefits when combined with incretin-based treatments. The findings, presented at the ADA Scientific Sessions, support the development of next-gen APJ agonists to address obesity and key metabolic comorbidities.

$BIOA https://wallstreetwaves.com/bioage-labs-inc-reports-promising-preclinical-results-for-apj-agonist-in-enhancing-glycemic-control-and-c

A publicly traded company on the Nasdaq wants to develop breakthrough new drugs for longevity. And now, they’re partnering up with a biobank in Norway to do it. $BIOA https://www.thenew.money/article/bioage-labs-is-making-a-bold-bet-on-biobank-data

$BIOA eod spike is huge will add more

$BIOA if they can announce they are using AI to sort through the drugs 😎😂😂

76% realized gain in pre-market trading from 7 am till now (2 hours of work). 5 out of 5 winning trades on $FGL, $BKYI, $DATS and $BIOA. while other just keep talking and staring at screens, we locked in the profits and leaving penny stocks now to trade options and futures.

$BIOA can’t seem to find out why this popped pre market ???

$BIOA Run baby run!

13% win on the $BIOA trade. Closed the rest 50% short position at even better price @ 4.75. https://stocktwits.com/MHM7700/message/618126706